Search research articles
Contact Us
Filters
Showing results (111-120 of 133) with videos related to
Page
of 14
Sort By:
Blood Advances
|
January 9, 2025
Advancing drug development in myelodysplastic syndromes
Alain Mina, Kathy L McGraw, Lea Cunningham, et al.
Archives of Pathology & Laboratory Medicine
|
March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Savanah D Gisriel, Fnu Aakash, John M Bennett, et al.
Leukemia & Lymphoma
|
September 12, 2022
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry
Rena Buckstein, Lisa Chodirker, Lee Mozessohn, et al.
British Journal of Haematology
|
July 6, 2017
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis
Heather A Leitch, Ambica Parmar, Richard A Wells, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group
Diego Villa, Michael Crump, Tony Panzarella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12
Michael Crump, John Kuruvilla, Stephen Couban, et al.
Leukemia & Lymphoma
|
November 9, 2024
Improvement in quality of life in MDS patients who become transfusion independent after treatment
Bo A Wan, Shabbir M H Alibhai, Lisa Chodirker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2021
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero, Valeria Santini, Antonio Almeida, et al.
Leukemia
|
August 29, 2020
Revised 15-item MDS-specific frailty scale maintains prognostic potential
Bo A Wan, Aziz Nazha, Rebecca Starkman, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 133) with videos related to
Sort By:
Page
of 14
Blood Advances
|
January 9, 2025
Advancing drug development in myelodysplastic syndromes
Alain Mina, Kathy L McGraw, Lea Cunningham, et al.
Archives of Pathology & Laboratory Medicine
|
March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Savanah D Gisriel, Fnu Aakash, John M Bennett, et al.
Leukemia & Lymphoma
|
September 12, 2022
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry
Rena Buckstein, Lisa Chodirker, Lee Mozessohn, et al.
British Journal of Haematology
|
July 6, 2017
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis
Heather A Leitch, Ambica Parmar, Richard A Wells, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group
Diego Villa, Michael Crump, Tony Panzarella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12
Michael Crump, John Kuruvilla, Stephen Couban, et al.
Leukemia & Lymphoma
|
November 9, 2024
Improvement in quality of life in MDS patients who become transfusion independent after treatment
Bo A Wan, Shabbir M H Alibhai, Lisa Chodirker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2021
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero, Valeria Santini, Antonio Almeida, et al.
Leukemia
|
August 29, 2020
Revised 15-item MDS-specific frailty scale maintains prognostic potential
Bo A Wan, Aziz Nazha, Rebecca Starkman, et al.
Page
of 14